Encouraging Partnership and Collaboration for Success in the Field of R&D for Global Health

Transcription

1 Encouraging Partnership and Collaboration for Success in the Field of R&D for Global Health Fil Randazzo, Ph.D. Deputy Director Global Health Discovery & Translational Sciences

2 EVERY PERSON DESERVES THE CHANCE TO LIVE A HEALTHY, PRODUCTIVE LIFE.

3 Our Resources R&D for Neglected Diseases: $450M in grants (2011) We work through partners We invest by providing grants to those partners March 12,

4 Some Perspective $450M is a lot of money, but it s really not a lot of money 2011 Health R&D Spend US NIH $30.7B Roche $ 9.6B Gates Foundation $ 0.45B We need to be strategic and smart with our investments March 12,

5 How We Prioritize Our Work Four filters Greatest burden Infectious diseases, nutrition, and reproductive, maternal, and neonatal health. Widest imbalance Problems that disproportionately affect poor countries Gaps in attention Fill in areas receiving inadequate attention and resources Greatest long term impact Focus largely on prevention. Invest in long term breakthroughs

6 Investment Philosophy Form critical partnerships. Take big risks. Find scalable, sustainable solutions. Leverage science and technology. Leverage our voice to increase resources and attention on global health (Advocacy). March 12,

7 Ways We Partner Co-funding: complementing comparative advantages Funding diverse organizations through multiple mechanisms including Product development partnerships (PDPs) Partnerships with Pharma Research grants Direct investments in promising new technologies These partnerships are vital, and have yielded successes that are saving lives March 12,

8 Successful Partnerships: PDPs have launched 20 products 1. ASAQ (DNDi) 17. CareHPV (PATH) 2. ASMQ (DNDi) 18. Paromomycin Intramuscular Injection 3. Pediatric Benznidazole (DNDi) (PATH/OWH) 4. Xpert MTB/RIF (FIND) 19. Actellic CS Indoor Residual Spray (IVCC) 5. Liquid culture & DST (FIND) 20. leprosy rapid diagnostic test (IDRI) 6. Rapid speciation for MDR TB (FIND) 7. LPA line probe assay (FIND) 8. Fluorescence microscopy (FIND) 9. KalazarDetect (IDRI) 10. Inactivated oral cholera vaccine (IVI) 11. Coartem Dispersible (MMV) 12. Injectable artesunate (MMV) 13. Eurartesim DHA-piperaquine (MMV) 14. Pyramax (pyronaridine-artesunate) (MMV) 15. MenAfriVac (PATH/MVP) 16. JE Vaccine India (PATH) 1. Not funded by the Bill & Melinda Gates Foundation Source: PDP-provided pipeline and product launch data; The New Landscape of Neglected Disease Drug Research and Development, Photographs are copyright of FIND, MMV, DNDi 8

9 Successful Partnerships: MenAfriVac Delivery and Impact 2010 ~ 20 Million vaccinated 2011 ~ 35 Million vaccinated 2012 ~ 55 Million to be vaccinated Dramatic reduction in reported meningitis cases and in epidemic districts Disappearance of Group A meningitis Stable fraction of non Group A meningococcal isolates Absence of Group A in carriage studies 9

10 The European Union s Role in Partnering for Global Health Success The European Union is a Critical Partner >359 products are now in development for poverty-related neglected diseases (PRND) 43% involving European developers For vaccines alone, there are promising candidates for: Buruli ulcer Tuberculosis Schistosomiasis Saving Lives and Creating Impact: EU investment in poverty-related neglected diseases. 17 October DSW (Deutsche Stiftung Weltbevoelkerung) and Policy Cures. 10

11 Looking Ahead and Potential Partnerships Next-Generation Malaria Vaccines Translational Approaches to HIV and TB Vaccine Research Novel treatments and vaccines for neglected diseases Accelerating regulatory harmonization Win-Win Partnerships Key intersections with EDCTP and other programs under Horizon 2020 Promotes co-investment and thought partnership Sustains EU leadership in global health innovation Accelerates development + delivery of life-saving tools Creates thousands of highly skilled jobs globally March 12,

12 Our Belief ALL LIVES NO MATTER WHERE THEY ARE BEING LIVED HAVE EQUAL VALUE